Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia: Efficacy and Safety

Medicine, Hematology, Oncology,
Revumenib   KMT2A-rearranged   acute leukemia   relapsed   refractory   safety   efficacy  

Academic Background Acute leukemia is a malignant hematologic disease caused by genetic mutations in hematopoietic cells, characterized by a block in differentiation during hematopoiesis and uncontrolled cellular proliferation. Among these, KMT2A gene rearrangements (KMT2A-rearranged, KMT2Ar) occur in up to 10% of acute leukemias in children and ad...

Revumenib Revises the Treatment Landscape for KMT2A-R Leukemia

Medicine, Hematology, Oncology,
Revumenib   KMT2A-R leukemia   menin inhibitors   gene expression   clinical trial   leukemia cell differentiation   drug resistance  

Revumenib Alters the Treatment Landscape for KMT2A-Rearranged Leukemia Academic Background Leukemia is a malignant disease caused by abnormalities in the hematopoietic system, with KMT2A-rearranged (KMT2A-r) leukemia being a common subtype, particularly in pediatric and adult acute myeloid leukemia (AML). Rearrangements of the KMT2A gene (lysine me...